These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20809642)

  • 21. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
    Battle MR; Goggi JL; Allen L; Barnett J; Morrison MS
    J Nucl Med; 2011 Mar; 52(3):424-30. PubMed ID: 21321268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.
    Li LS; Rader C; Matsushita M; Das S; Barbas CF; Lerner RA; Sinha SC
    J Med Chem; 2004 Nov; 47(23):5630-40. PubMed ID: 15509162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity.
    Wijtmans M; de Graaf C; de Kloe G; Istyastono EP; Smit J; Lim H; Boonnak R; Nijmeijer S; Smits RA; Jongejan A; Zuiderveld O; de Esch IJ; Leurs R
    J Med Chem; 2011 Mar; 54(6):1693-703. PubMed ID: 21348462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature.
    Cao L; Du P; Jiang SH; Jin GH; Huang QL; Hua ZC
    Mol Cancer Ther; 2008 Apr; 7(4):851-61. PubMed ID: 18413798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors through click chemistry.
    Shen J; Woodward R; Kedenburg JP; Liu X; Chen M; Fang L; Sun D; Wang PG
    J Med Chem; 2008 Dec; 51(23):7417-27. PubMed ID: 19007204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy.
    Kim JH; Kim YS; Park K; Kang E; Lee S; Nam HY; Kim K; Park JH; Chi DY; Park RW; Kim IS; Choi K; Chan Kwon I
    Biomaterials; 2008 Apr; 29(12):1920-30. PubMed ID: 18289669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis.
    McQuade P; Knight LC; Welch MJ
    Bioconjug Chem; 2004; 15(5):988-96. PubMed ID: 15366951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hybrid angiogenesis inhibitors: synthesis and biological evaluation of bifunctional compounds based on 1-deoxynojirimycin and aryl-1,2,3-triazoles.
    Zhou Y; Zhao Y; O' Boyle KM; Murphy PV
    Bioorg Med Chem Lett; 2008 Feb; 18(3):954-8. PubMed ID: 18166456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3.
    Ludbrook SB; Barry ST; Delves CJ; Horgan CM
    Biochem J; 2003 Jan; 369(Pt 2):311-8. PubMed ID: 12358597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RGD-mutants of B-lymphotropic polyomavirus capsids specifically bind to alpha(v)beta3 integrin.
    Langner J; Neumann B; Goodman SL; Pawlita M
    Arch Virol; 2004 Oct; 149(10):1877-96. PubMed ID: 15290355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics.
    Kok RJ; Schraa AJ; Bos EJ; Moorlag HE; Asgeirsdóttir SA; Everts M; Meijer DK; Molema G
    Bioconjug Chem; 2002; 13(1):128-35. PubMed ID: 11792188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RGD-Targeted Ultrasound Contrast Agent for Longitudinal Assessment of Hep-2 Tumor Angiogenesis In Vivo.
    Hu Q; Wang XY; Kang LK; Wei HM; Xu CM; Wang T; Wen ZH
    PLoS One; 2016; 11(2):e0149075. PubMed ID: 26862757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrin-targeted AmpRGD sunitinib liposomes as integrated antiangiogenic tools.
    Bianchini F; De Santis A; Portioli E; Russo Krauss I; Battistini L; Curti C; Peppicelli S; Calorini L; D'Errico G; Zanardi F; Sartori A
    Nanomedicine; 2019 Jun; 18():135-145. PubMed ID: 30849548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth.
    Park K; Kim YS; Lee GY; Park RW; Kim IS; Kim SY; Byun Y
    Pharm Res; 2008 Dec; 25(12):2786-98. PubMed ID: 18581207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ynamide Click chemistry in development of triazole VEGFR2 TK modulators.
    Vojtičková M; Dobiaš J; Hanquet G; Addová G; Cetin-Atalay R; Yildirim DC; Boháč A
    Eur J Med Chem; 2015 Oct; 103():105-22. PubMed ID: 26344911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclization of peptides through a urea bond: application to the Arg-Gly-Asp tripeptide.
    Schmidt J; Garambois V; Rocheblave L; Martinez J; Pèlegrin A; Cavelier F; Vivès E
    Chembiochem; 2010 May; 11(8):1083-92. PubMed ID: 20422669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
    Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A convergent synthesis of new beta-turn mimics by click chemistry.
    Oh K; Guan Z
    Chem Commun (Camb); 2006 Aug; (29):3069-71. PubMed ID: 16855688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.
    Ryppa C; Mann-Steinberg H; Biniossek ML; Satchi-Fainaro R; Kratz F
    Int J Pharm; 2009 Feb; 368(1-2):89-97. PubMed ID: 18992308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.